Perry Sternberg
Venture Partner at Visionary Ventures
About
Over 30 years of commercial leadership across ophthalmology, with 15 years in eye care spanning roles at Novartis, Bausch & Lomb, and Shire. Key contributor to the FDA approval and launch of Xiidra for dry eye disease and participated in Shire's acquisition by Takeda.
Colleagues at Visionary Ventures
Bill Carpou
Investor at Visionary Ventures
Bob Avery
Investor at Visionary Ventures
Daniel Gil
Venture Partner at Visionary Ventures
Dick Lindstrom
Investor at Visionary Ventures
Ehsan Sadri
Investor at Visionary Ventures
Garrett Hamontree
Partner & CFO at Visionary Ventures
Jeffry Weinhuff
Managing Partner at Visionary Ventures
Toby Tyson
Investor at Visionary Ventures